Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novartis : Researchers at Novartis Report New Data on Medicinal Chemistry [Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:24pm CEST

Researchers at Novartis Report New Data on Medicinal Chemistry [Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors]

By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Health and Medicine - Medicinal Chemistry are presented in a new report. According to news reporting out of Basel, Switzerland, by NewsRx editors, research stated, "The predominant expression of phosphoinositide 3-kinase d (PI3Kd) in leukocytes and its critical role in B and T cell functions led to the hypothesis that selective inhibitors of this isoform would have potential as therapeutics for the treatment of allergic and inflammatory disease. Targeting specifically PI3Kd should avoid potential side effects associated with the ubiquitously expressed PI3Ka and b isoforms."

Our news journalists obtained a quote from the research from Novartis, "We disclose how morphing the heterocyclic core of previously discovered 4,6-diaryl quinazolines to a significantly less lipophilic 5,6,7,8-tetrahydropyrido[4,3-]pyrimidine, followed by replacement of one of the phenyl groups with a pyrrolidine-3-amine, led to a compound series with an optimal on-target profile and good ADME properties. A final lipophilicity adjustment led to the discovery of CDZ173 (leniolisib), a potent PI3Kd selective inhibitor with suitable properties and efficacy for clinical development as an anti-inflammatory therapeutic. , CDZ173 inhibits a large spectrum of immune cell functions, as demonstrated in B and T cells, neutrophils, monocytes, basophils, plasmocytoid dendritic cells, and mast cells. , CDZ173 inhibits B cell activation in rats and monkeys in a concentration-and time-dependent manner. After prophylactic or therapeutic dosing, CDZ173 potently inhibited antigen-specific antibody production and reduced disease symptoms in a rat collagen-induced arthritis model. Structurally, CDZ173 differs significantly from the first generation of PI3Kd and PI3Kgd-selective clinical compounds. Therefore, CDZ173 could differentiate by a more favorable safety profile."

According to the news editors, the research concluded: "CDZ173 is currently in clinical studies in patients suffering from primary Sj?gren's syndrome and in APDS/PASLI, a disease caused by gain-of-function mutations of PI3Kd."

For more information on this research see: Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. Acs Medicinal Chemistry Letters, 2017;8(9):975-980. (American Chemical Society - www.acs.org; Acs Medicinal Chemistry Letters - www.pubs.acs.org/journal/amclct)

Our news journalists report that additional information may be obtained by contacting K. Hoegenauer, Global Discovery Chemistry, PK Sciences, Chemical Biology and Therapeutics and Autoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland. Additional authors for this research include N. Soldermann, F. Zecri, R.S. Strang, N. Graveleau, R.M. Wolf, N.G. Cooke, A.B. Smith, G.J. Hollingworth, J. Blanz, S. Gutmann, G. Rummel, A. Littlewood-Evans and C. Burkhart (see also Health and Medicine - Medicinal Chemistry).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acsmedchemlett.7b00293. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Basel, Europe, Switzerland, Health and Medicine, Medicinal Chemistry.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10/19 NOVARTIS : Recent Findings from Novartis Provide New Insights into Glucosyltrans..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 NOVARTIS : Drug Revolade(R) Shows Long-Term Disease Control for Chronic/Persiste..
10/19 NOVARTIS : sheds generics plant and 450 jobs amid pricing pressure
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 NOVARTIS : 450 jobs to go as pricing pressures push Novartis to close CO generic..
10/18 NOVARTIS : drug Revolade® shows long-term disease control for chronic/persistent..
10/13 NOVARTIS : Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoretinal ..
10/13 NOVARTIS : 65-- Alcon Laboratories, Inc. Constellation LXT Vitrectomy/ Vitreoret..
10/13 NOVARTIS AG (ADR)(NYSE : NVS) Says It Will Not Sell Its Stake In Roche
More news
News from SeekingAlpha
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
10/19 YOUR DAILY PHARMA SCOOP : Gilead's Brave New World, AZN's Lynparza SNDA, RXDX En..
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
Financials ($)
Sales 2017 48 864 M
EBIT 2017 11 614 M
Net income 2017 7 295 M
Debt 2017 17 700 M
Yield 2017 3,32%
P/E ratio 2017 24,53
P/E ratio 2018 21,59
EV / Sales 2017 5,00x
EV / Sales 2018 4,78x
Capitalization 226 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 404
JOHNSON & JOHNSON23.29%382 202
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501